Steven Devine, MD, Discusses Exciting Abstracts From ASH 2021

Video

Steven Devine, MD, spoke about which abstracts he found most interesting at ASH 2021.

At the 2021 American Society of Hematology Annual Meeting, Steven Devine, MD, chief medical officer of the National Marrow Donor Program/Be the Match and associate scientific director for Center for International Blood and Marrow Transplant Research (CIBMTR), discussed abstracts that he found particularly interesting. He started the discussion with the ZUMA-7 trial (NCT03391466), which utilized axicabragene ciloleucel (axi-cel; Yescarta) compared with standard of care in patients with relapsed/refractory large B-cell lymphoma. Patients treated with axi-cel had a significant improvement in event-free survival as well as quality-of-life measures.1,2

Transcript:

The ZUMA-7 abstract that was presented at the plenary session and has been published in the New England Journal of Medicine was potentially practice changing. The point that was made during the plenary session is that we need to do a better job enrolling a diverse set of patients, and this is certainly a message for the blood and marrow transplant field.

From the transplant perspective, there was another CIBMTR analysis looking at the impact of donors and outcomes in patients with lymphoma. We compared haploidentical donors to matched unrelated donors and virtually all outcomes favored the use of matched unrelated donors over haploidentical donors if post-transplant cyclophosphamide is used for graft-versus-host disease prophylaxis. That’s the second study that’s analyzed if post-transplant cyclophosphamide is used, that matched unrelated donor might be favored over haploidentical donor if the unrelated donor is readily available.

References

1. Locke FL, Miklos DB, Jacobson C, et al. Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Presented at the 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Atlanta, GA. Abstract 2. https://bit.ly/33q8RFy

2. Elsawy M, Chavez J, Avivi I, et al. Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). Presented at the 63rd American Society of Hematology Annual Meeting; December 11-14, 2021. Atlanta, GA. Abstract 430.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content